Skip to content

Single-Cell Transcriptomics of the Peritoneal Microenvironment of Colorectal PC

The Role of the Peritoneal Microenvironment in the Pathogenesis of Colorectal Peritoneal Carcinomatosis: Single-cell Transcriptomics

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05676372
Acronym
SingleCell
Enrollment
50
Registered
2023-01-09
Start date
2020-06-16
Completion date
2025-12-31
Last updated
2023-12-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peritoneal Metastases

Brief summary

Single cell transcriptomics of CRC PC samples

Detailed description

Research methodology Before inclusion of patients, patients will be screened for the presence of hepatitis B, hepatitis C and HIV to ensure researcher safety. During cytoreductive surgery, a total of five samples of tumoral tissue will be acquired. Three of those samples will be utilized for ScRNASeq analysis, and two samples of a macrometastasis will be snap frozen and cryopreserved. Single-cell RNA-Sequencing analysis We will comprehensively catalog the stromal cell types in the microenvironment of colorectal cancer peritoneal metastases utilizing single-cell RNA sequencing (scRNAseq) on three samples (one of which should preferably originate from the omentum majus, to encompass milky spots) acquired from surgical waste material of patients undergoing cytoreductive surgery. After sample prelevation, samples will be transported as soon as possible while cooled and submerged in 10% PBS to the VIB facilities, where single cell suspensions will be made according to standard protocols. After cell selection by FACS (CD45+ and live/dead stain, to ensure a 50/50 mix of immune and stromal cells) and library prep, ScRNASeq will be performed. Single cell sequencing analysis will allow us to identify cell clusters that by usage of marker genes will be assigned to different known cell lineages. After annotation of data, a landscape of the composition of the tumor stroma will be acquired.

Interventions

PROCEDURECRC+HIPEC

Sample prelevation of cytoreductive surgery

Sponsors

Flemish institute of biotechnology (VIB)
CollaboratorOTHER
University Hospital, Ghent
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Patients undergoing CRS+HIPEC for PC of colorectal origin

Exclusion criteria

* Previous HIPEC/PIPAC

Design outcomes

Primary

MeasureTime frameDescription
Single-cell transcriptomics24 monthsA transcriptional single-cell RNA seq atlas of gene expression data will be reported

Countries

Belgium

Contacts

Primary ContactWim P Ceelen, MD, PhD
wim.ceelen@ugent.be093326251
Backup ContactJesse G Demuytere, MD
jesse.demuytere@ugent.be093324278

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026